Forget Wall Street’s Ultimate Pharma Value Trap: Here Is a Far Better Stock to Buy Right Now

Bristol Myers Squibb (NYSE:BMY | BMY Price Prediction) is the headline pharma name dividend hunters keep circling, drawn in by a 4.37% yield and a forward P/E of 9 that screams cheap. But the underlying numbers tell a different story.

That low multiple is cheap for a reason. Bristol Myers is running headfirst into a generic cliff that the Growth Portfolio cannot fully paper over. Revlimid collapsed to $349 million in Q1 2026, down 63% year over year, Pomalyst fell 22% to $513 million after generic pomalidomide entered the U.S. market in March 2026, and Sprycel dropped 58%. Management is guiding the Legacy Portfolio to decline 12% to 16% for the full year.

The damage already shows in the earnings line. Q1 2026 non-GAAP EPS came in at $1.58, down from $1.80 a year earlier. Q4 2025 EPS missed consensus by 22.70%, and full-year 2026 EPS guidance of $6.05 to $6.35 now sits below 2025’s actual $6.15. The pipeline is throwing red flags too: the Reblozyl INDEPENDENCE trial in myelofibrosis failed, and the Milvexian Librexia ACS trial was stopped for lack of efficacy. Layer on roughly $33.6 billion in net debt, and the value angle starts looking like a trap. Eighteen of 29 analysts sit on Hold for a reason.

Why AbbVie Looks Stronger

AbbVie (NYSE:ABBV) already did the hard thing Bristol Myers still has to do. Three reasons it stands out right now.

1. The post-Humira transition is a finished story. Q1 2026 revenue hit $15.00 billion, up 12.4% year over year, beating the $14.72 billion consensus. Skyrizi delivered $4.48 billion, up 30.9%, and Rinvoq added $2.12 billion, up 23.3%. Those two more than absorbed the 38.6% decline in Humira to $688 million. Management responded by raising 2026 adjusted EPS guidance to $14.08 to $14.28.

2. The growth engine spans four therapeutic areas. Neuroscience pulled in $2.88 billion, up 26.0%, with Ubrelvy growing 41.4% and Qulipta up 53.6%. Botox Cosmetic rose 20.2% as aesthetics recovered. The FDA approved Venclexta with acalabrutinib as the first all-oral fixed-duration CLL regimen, and the non-incretin obesity candidate ABBV-295 showed clinically meaningful weight loss in Phase 1. That is diversification at scale.

3. The capital story is real. AbbVie is plowing $1.4 billion into a 185-acre Durham, NC manufacturing campus and $380 million into two new North Chicago API facilities, while operating at a 62.3% return on equity and a 70.2% gross margin. The quarterly dividend was raised 5.5% to $1.73 per share. CEO Robert A. Michael put it plainly: “We are off to an excellent start in 2026, with first-quarter results exceeding our expectations.”

The setup is straightforward. One stock is fighting gravity, with shares down 6.46% over the past month as the generic erosion thesis hardens. The other is compounding, with AbbVie up 18.97% over the past year and 131.74% over five years. For retirement-focused investors weighing pharma exposure, AbbVie’s execution and diversification stand out against Bristol Myers’ unproven turnaround.